The content of immunoinflammation markers in peripheral blood mononuclears in alcohol dependence and affective disorders

Background: the involvement of immune system in the development of affective disorders and alcohol dependence is recognized widely, while the contribution of immunoinflammation to the pathophysiology of combined forms of affective and addictive disorders remains insufficiently studied.

The aim of this work was to investigate the clinical and dynamic features and to study the concentration of cytokines IL-1α, IL-1β, TNFα, IL-10, IL-13, TGFα in peripheral blood mononuclear cells of patients with alcohol dependence syndrome, affective disorder and comorbidity of alcohol dependence and affective disorder.

Patients and Methods: 86 patients with alcohol dependence syndrome and affective disorders (F10.2, F31.3-31.5, F32, F33, ICD10) were examined. The SIGH-SAD, CGI and HARS scales were used. The concentration of cytokines in lysates of peripheral blood mononuclear cells was determined using the Magnetic Lumine Assay Kit (Cloud-Clone Corp., China) and xMAP Technology on a Magpix analyzer (Luminex, USA).

Results: the lowest severity of the disease characterized the patients with isolated alcoholism, while the longest duration of both affective and alcoholic diseases, the severity of the disease, and the intensity of anxiety disorders were found in patients with comorbidity of disorders. Patients are characterized by the increase of cytokines IL-1α and IL-1β in patients with isolated affective and addictive disorders. Patients with comorbidity of disorders are distinguished by a decrease in the content of the studied proand anti-inflammatory cytokines.

Conclusion: the conducted study revealed features in the clinical dynamics and spectrum of cytokines in patients with alcohol dependence, affective disorders and their comorbid course.

1. GBD 2021 Risk Factors Collaborators Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990- 2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2162–2203. doi: 10.1016/S0140-6736(24)00933-4

2. Boxan NA, Roshhina OV, Schastny`j ED, Simutkin GG, Ivanova SA. Komorbidnost` affektivny`x rasstrojstv i alkogol`noj zavisimosti: kollektivnaya monografiya. Tomsk: Integral`ny`j pereplet, 2021:144. (In Russ.).

3. Kaleda VG. Depression is the leading problem of clinical psychiatry. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123:(11–2):7–8. (In Russ.). doi: 10.17116/jnevro20231231127

4. Krasnov VN. Depression: a large-scale problem, and possibilities to overcome it. Mental health. 2023;18(8):68–69. (In Russ.). doi: 10.25557/2074-014X.2023.08.68-69

5. Bessonova L, Ogden K, Doane MJ, O'Sullivan AK, Tohen M. The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review. Clinicoecon Outcomes Res. 2020;12:481–497. doi: 10.2147/CEOR.S259338

6. Culpepper L, Martin A, Nabulsi N, Parikh M. The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis. Adv Ther. 2024;41(5):1860–1884. doi: 10.1007/s12325-024-02817-w

7. Rehm J, Shield KD. Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr Psychiatry Rep. 2019;21(2):10. doi: 10.1007/s11920-019-0997-0

8. Saha S, Lim CC, Degenhardt L, Cannon DL, Bremner M, Prentis F, Lawrence Z, Heffernan E, Meurk C, Reilly J, McGrath JJ. Comorbidity between mood and substance-related disorders: A systematic review and meta-analysis. Aust N Z J Psychiatry. 2022;56(7):757– 770. doi: 10.1177/00048674211054740

9. Neupane SP. Neuroimmune Interface in the Comorbidity between Alcohol Use Disorder and Major Depression. Front Immunol. 2016; 7:655. doi: 10.3389/fimmu.2016.00655

10. Vasilieva SN, Simutkin GG, Schastnyy ED, Bokhan NA. Clinical-Dynamic Features of Affective Disorders Comorbid with Alcohol Dependence. Int J Ment Health Addiction. 2022;20:3221. https://doi.org/10.1007/s11469-020-00269-1

11. Ivanova SA, Losenkov IS, Levchuk LA, Bojko AS, Vyalova NM, Simutkin GG, Boxan NA. Depressivny`e rasstrojstva: gipotezy` patogeneza i potencial`ny`e biologicheskie markery`. Novosibirsk, Izd-vo SO RAN, 2018:199. (In Russ.).

12. Leonard BE, Wegener G. Inflammation, insulin resistance and neuroprogression in depression. Acta Neuropsychiatr. 2020;32(1):1–9. doi: 10.1017/neu.2019.17

13. Loonen AJ, Ivanova SA. Circuits Regulating Pleasure and Happiness-Mechanisms of Depression. Front Hum Neurosci. 2016;10;10:571. doi: 10.3389/fnhum.2016.00571

14. Mikhalitskaya EV, Vyalova NM, Bokhan NA, Ivanova SA. Alcohol-Induced Activation of Chemokine System and Neuroinflammation Development. Biochemistry (Mosc). 2024;89(11):1889–1903. doi: 10.1134/S0006297924110038

15. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446– 57. doi: 10.1016/j.biopsych.2009.09.033

16. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M, Veronese N, Herrmann N, Raison CL, Miller BJ, Lanctôt KL, Carvalho AF. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135(5):373–387. doi: 10.1111/acps.12698

17. Zozulya SA, Omelchenko MA, Otman IN, Sarmanova ZV, Migalina VV, Kaleda VG, Klyushnik TP. Features of inflammatory reactions in patients with juvenile depression with a clinically high risk of psychosis. S.S. Korsakov Journal of Neurology and Psychiatry.2023;123(11–2):55–61. (In Russ.). doi: 10.17116/jnevro202312311255

18. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res. 2006;30(4):720–30. doi: 10.1111/j.1530-0277.2006.00084.x

19. Fujimoto M, Uemura M, Nakatani Y, Tsujita S, Hoppo K, Tamagawa T, Kitano H, Kikukawa M, Ann T, Ishii Y, Kojima H, Sakurai S, Tanaka R, Namisaki T, Noguchi R, Higashino T, Kikuchi E, Nishimura K, Takaya A, Fukui H. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res. 2000;24(4 Suppl):48S–54S.

20. Hillmer AT, Nadim H, Devine L, Jatlow P, O'Malley SS. Acute alcohol consumption alters the peripheral cytokines IL-8 and TNF-α. Alcohol. 2020;85:95–99. doi: 10.1016/j.alcohol.2019.11.005

21. Szabo G, Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res. 2009;33(2):220–32. doi: 10.1111/j.1530-0277.2008.00842.x

22. Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M, Delzenne NM, de Timary P. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain Behav Immun. 2012;26(6):911–8. doi: 10.1016/j.bbi.2012.04.001

23. Neupane SP, Lien L, Martinez P, Aukrust P, Ueland T, Mollnes TE, Hestad K, Bramness JG. High frequency and intensity of drinking may attenuate increased inflammatory cytokine levels of major depression in alcohol-use disorders. CNS Neurosci Ther. 2014;20(10):898–904. doi: 10.1111/cns.12303

24. Archer M, Niemelä O, Luoto K, Kultti J, Hämäläinen M, Moilanen E, Koivukangas A, Leinonen E, Kampman O. Status of inflammation and alcohol use in a 6-month follow-up study of patients with major depressive disorder. Alcohol. 2019;81:21–26. doi: 10.1016/j.alcohol.2019.02.001

25. Mednova IA, Levchuk LA, Boiko AS, Roschina OV, Simutkin GG, Bokhan NA, Loonen AJM, Ivanova SA. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity. World J Biol Psychiatry. 2023;24(3):243–253. doi: 10.1080/15622975.2022.2095439

26. Vasilieva SN, Simutkin GG, Schastnyy ED, Lebedeva EV, Bokhan NA. Affective disorders in comorbidity with alcohol addiction: clinical and dynamic features, social adaptation level of patients. Bulletin of Siberian Medicine. 2020;19(1):29–35. (In Russ.). doi: 10.20538/1682-0363-2020-1-29-35

27. Vasilieva SN, Simutkin GG, Schastnyy ED, Surovtseva AK, Ukraintsev II, Altynbekov KS. Combination of mood disorders and alcohol dependence: clinical significance of comorbidity, social adaptation of patients. Siberian Herald of Psychiatry an Addiction Psychiatry. 2022;4(117):14–21. (In Russ.). doi: 10.26617/1810-3111-2022-4(117)-14-21

28. Andersson U, Tracey KJ. Reflex principles of immunological homeostasis. Annu Rev Immunol. 2012;30:313–335. doi: 10.1146/annurev-immunol-020711-075015

29. Felger JC. Role of Inflammation in Depression and Treatment Implications. Handb Exp Pharmacol. 2019;250:255–286. doi: 10.1007/164_2018_166

30. Dhabhar FS, Malarkey WB, Neri E, McEwen BS. Stress-induced redistribution of immune cells — from barracks to boulevards to battlefields: a tale of three hormones — Curt Richter Award Winner. Psychoneuroendocr. 2012;37(9):1345–1368. doi: 10.1016/j.psyneuen.2012.05.008

31. Coulter L, Ibrahimi M, Patel R, Agius M. Linking the psychosocial aetiology and neurobiology of unipolar depression. Psychiatr Danub. 2017;29(3):441–446.

32. Le Bras A. Chronic stress and inflammation. Lab Anim (NY). 2021;50(11):309. doi: 10.1038/s41684-021-00884-y

33. Vandewalle J, Luypaert A, De Bosscher K, Libert C. Therapeutic Mechanisms of Glucocorticoids. Trends Endocrinol Metab. 2018;29(1):42–54. doi: 10.1016/j.tem.2017.10.010

34. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27. doi: 10.1111/imr.12621

35. Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, Sota J, Dinarello CA. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20(3):102763. doi: 10.1016/j.autrev.2021.102763

36. Dinarello CA. Immunological and infiammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550. doi: 10.1146/annurev.immunol.021908.132612

37. Leclercq S, De Saeger C, Delzenne N, de Timary P, Stärkel P. Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence. Biol Psychiatry. 2014;76(9):725– 33. doi: 10.1016/j.biopsych.2014.02.003

38. Kang JS, Yoon YD, Lee KH, Park SK, Kim HM. Costunolide inhibits interleukin-1beta expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells. Biochem Biophys Res Commun. 2004;313(1):171–7. doi: 10.1016/j.bbrc.2003.11.109

39. Vasilyeva EF, Savushkina OK, Prokhorova TA, Tereshkina EB, Boksha IS, Sizov SV, Oleichik IV. Proinflammatory activity of monocytes and activity of glutathione-dependent enzymes in red blood cells in women with depressive conditions. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(6):120-125. doi: 10.26617/1810-3111-2022-4(117)-14-21

40. Lobo-Silva D, Carriche GM, Castro AG, Roque S, Saraiva M. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation. 2016;13(1):297. doi: 10.1186/s12974-016-0763-8

41. Bialek K, Czarny P, Watala C, Wigner P, Talarowska M, Galecki P, Szemraj J, Sliwinski T. Novel association between TGFA, TGFB1, IRF1, PTGS2 and IKBKB single-nucleotide polymorphisms and occurrence, severity and treatment response of major depressive disorder. PeerJ. 2020;8:e8676. doi: 10.7717/peerj.8676